FDA approves OLYSIO (simeprevir)
Janssen Therapeutics, Division of Janssen Products, LP (Janssen), announced today the U.S. Food and Drug Administration (FDA) has approved OLYSIO™ (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis. OLYSIO™ may benefit patients with chronic hepatitis C, including those who are treatment naive or who have failed prior interferon-based therapy.
Chronic hepatitis C is a blood-borne infectious disease of the liver that affects approximately 3.2 million people in the United States.
Continue reading this entire article: